Buprenorphine for the Management of Opioid Withdrawal
University of Adelaide, Department of Clinical and Experimental Pharmacology, DASC Evidence-Bsed Practice Unit, Adelaide, AUSTRALIA, 5005. Cochrane database of systematic reviews (Online)
(Impact Factor: 6.03).
02/2006; 2(2):CD002025. DOI: 10.1002/14651858.CD002025.pub3
Buprenorphine has potential as a medication to manage withdrawal from heroin, and possibly methadone. Dependence on opioid drugs (heroin, methadone) is a major health and social issue in many societies. Managed withdrawal from opioid dependence is an essential first step for drug-free treatment. The review of trials found that the drug buprenorphine has potential as a medication to reduce the signs and symptoms of withdrawal from heroin, and possibly methadone. These include irritability, anxiety, muscle and stomach pain, chills and nausea. The evidence is limited, but suggests that buprenorphine may be more effective than clonidine in reducing these signs and symptoms, and be associated with fewer adverse effects.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.